• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Daily Aspirin Increase Death Rates in Healthy Older Adults?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Daily aspirin use in healthy older adults has been found to be related to increased all-cause mortality
  • McNeil et al. (NEJM, 2018) went on to further assess the specific causes of death in the healthy elderly population

METHODS:

  • Secondary analysis of randomized controlled trial (RCT)
    • Aspirin in Reducing Events in the Elderly (ASPREE) trial
  • Participants: Individuals ≥70 years without cardiovascular disease, dementia, or disability
  • Participants received either
    • 100 mg enteric-coated aspirin
    • Placebo
  • Deaths were classified according to the underlying cause by adjudicators who were unaware of trial-group assignments

RESULTS:

  • 9,525 people were randomized
    • 1052 deaths occurred during a median of 4.7 years of follow-up
  • Risk of death from any cause
    • 12.7 events per 1000 person-years in the aspirin group
    • 11.1 events per 1000 person-years in the placebo group
    • Hazard ratio (HR) 1.14; 95% CI; 1.01 to 1.29
  • Cancer was the major contributor
    • 3.1% of the aspirin group
    • 2.3% of the placebo group
    • HR 1.31; 95% CI, 1.10 to 1.56
    • 1.6 excess deaths per 1000 person-years
    • No single cancer location or pathologic type was observed

CONCLUSION:

  • Aspirin lead to higher all-cause mortality in the elderly (≥70 years at enrollment) who did not have an indication for aspirin
  • The deaths were attributable primarily to cancer, not increased bleeding
    • Based on CI, this increase ranges from 1 to 29% of all-cause mortality
  • This result contradicts early studies and authors recommend interpreting the data with caution
    • This study is an RCT as opposed to many previous research studies which was based on meta-analyses
    • This study may have ended before a preventative benefit appeared

Learn More – Primary Sources:

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Low-Dose Aspirin Reduce Risk of First Cardiovascular Events in Individuals at Moderate Risk?
Patient with Stable CVD: Rivaroxaban, Aspirin or Both to Prevent Recurrent Events?
Low Dose Aspirin and Breast Cancer Prevention – Results from the CTS Cohort

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site